SOUTH SAN FRANCISCO, CA--(December 06, 2017) - VistaGen Therapeutics Inc.(NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, today announced the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,834,801 related to certain methods of production for AV-101, VistaGen's lead CNS product candidate.

 

"The issuance of this U.S. patent by the USPTO advances our intellectual property strategy for AV-101 at this vital period in its clinical development. This issued U.S. patent, in conjunction with the potential issuance of additional AV-101 patent applications currently under review worldwide, provides VistaGen with added long-term intellectual property protection for AV-101 and enhances its commercial potential," stated Shawn Singh, Chief Executive Officer of VistaGen.

VANCOUVER, BRITISH COLUMBIA--( Nov. 17, 2017) 

 

NOT FOR DISTRIBUTION TO UNITED STATED NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES AND DOES NOT CONSTITUTE AN OFFER IN THE UNITED STATES OF THE SECURITIES DESCRIBED HEREIN

 

Cannabix Technologies Inc. (CSE:BLO)(CSE:BLO.CN)(CNSX:BLO) (the "Company") is pleased to announce that it has entered into an agreement with Cormark Securities Inc. (the "Underwriter") pursuant to which the Underwriter has agreed to purchase 3,000,000 units ("Units") of the Company on a bought deal private placement basis at a price of $1.15 per Unit (the "Offering Price"), for gross proceeds of $3.45 million (the "Offering"). Each Unit shall consist of one common share (a "Common Share") of the Company and one common share purchase warrant. Each warrant will entitle the holder thereof to purchase one Common Share at a price equal to $1.60 for a period of 36 months following Closing.

WESTMINSTER, Colo., Nov. 16, 2017  -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced the European Patent Office’s issuance of a patent (EPO # 2515899) on methods of treating cardiovascular disease and conditions with a thiol-substituted isosorbide mononitrate based on genetic targeting.  The European patent, entitled “Methods and Compositions for Cardiovascular Diseases and Conditions,” provides protection for this novel approach to treating patients with cardiovascular disease and conditions.  The European patent has been validated in ten countries: Denmark, France, Germany, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland and the United Kingdom.  ARCA has related patent applications pending in the United States Patent Office and Canadian Intellectual Property Office.

- Recent entry into the cosmeceuticals sector with launch of proprietary line of products - Company continues advancement for expansion into the nutraceutical market - Completion of bio-efficacy study evaluating avenanthramides in exercise-induced inflammation with results expected by year-end - Results from animal studies evaluating bioavailability of impregnated CoQ10 with beta glucan expected Q1 2018

 

EDMONTON, ALBERTA--(Nov. 15, 2017) -Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company") a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the three-month and nine-month periods ended September 30, 2017 and provided an overview of recent operational highlights.

 

Financial Highlights for the Third Quarter 2017

Total sales of $3,600,000 for the quarter ended September 30, 2017 compared to $3,018,000 in Q3 2016;